# Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis

Study · id `cardio:ct-nct04282941` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04282941](<https://clinicaltrials.gov/study/NCT04282941>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04282941

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

## Technical summary

Registry record NCT04282941. Randomized; double masking; primary purpose treatment. Start 2017-02-20 (actual); primary completion 2020-01-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT04282941, source copy `cardio:ctgov-nct04282941-2020-10-29`, retrieved 2026-10-26)
- Started: 2017-02-20 (actual) (ClinicalTrials.gov record NCT04282941, source copy `cardio:ctgov-nct04282941-2020-10-29`, retrieved 2026-10-26)
- Primary completion: 2020-01-30 (actual) (ClinicalTrials.gov record NCT04282941, source copy `cardio:ctgov-nct04282941-2020-10-29`, retrieved 2026-10-26)
- Completion: 2020-11-30 (anticipated) (ClinicalTrials.gov record NCT04282941, source copy `cardio:ctgov-nct04282941-2020-10-29`, retrieved 2026-10-26)
- Countries: Spain (ClinicalTrials.gov record NCT04282941, source copy `cardio:ctgov-nct04282941-2020-10-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04282941-2020-10-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Clinical Trial to Evaluate Two Guidelines for the Administration of Ibuprofen in the Treatment of Persistent Ductus Arteriosus Eco-guided: Impact in the Intestinal Prognosis
- Acronym: IBU24h-EchoG
- Condition: Persistent Ductus Arteriosus
- Intervention (Drug): Ibuprofen in continuous (24 hours) iv infusion and EchoG
- Intervention (Drug): IV bolus Ibuprofen slow (15 minutes) and EchoG
- Lead sponsor: Instituto de Investigación Hospital Universitario La Paz
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Congenital heart disease (`core:congenital-heart-disease`)
- Registry lists this organization as the lead sponsor: Instituto de Investigación Hospital Universitario La Paz (`cardio:org-instituto-de-investigacion-hospital-universitario-la-paz`)

## Provenance

Content hash: 5f66547380db32282d4baa8fc67dc72ff10af2ca3e907170b6e1b91b4975abea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
